These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36510982)

  • 21. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
    [No Abstract]   [Full Text] [Related]  

  • 22. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRAME expression and its prognostic significance in invasive breast carcinoma.
    Korša L; Abramović M; Kovačević L; Milošević M; Podolski P; Prutki M; Marušić Z
    Pathol Res Pract; 2024 Feb; 254():155096. PubMed ID: 38219495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
    Murase K; Yanai A; Saito M; Imamura M; Miyagawa Y; Takatsuka Y; Inoue N; Ito T; Hirota S; Sasa M; Katagiri T; Fujimoto Y; Hatada T; Ichii S; Nishizaki T; Tomita N; Miyoshi Y
    Breast Cancer; 2014 Jan; 21(1):52-7. PubMed ID: 22359195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman.
    Setyawati Y; Rahmawati Y; Widodo I; Ghozali A; Purnomosari D
    Asian Pac J Cancer Prev; 2018 May; 19(5):1263-1268. PubMed ID: 29801411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
    Sun WY; Choi J; Cha YJ; Koo JS
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.
    Caldarella A; Puliti D; Crocetti E; Bianchi S; Vezzosi V; Apicella P; Biancalani M; Giannini A; Urso C; Zolfanelli F; Paci E
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):181-5. PubMed ID: 22961208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
    Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
    BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.
    Yang ZJ; Liu YX; Huang Y; Chen ZJ; Zhang HZ; Yu Y; Wang X; Cao XC
    Cancer Med; 2023 Feb; 12(3):2493-2504. PubMed ID: 35909232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of calretinin in high-grade hormone receptor-negative invasive breast carcinomas: correlation with histological and molecular subtypes.
    Micello D; Bossi A; Marando A; Dainese E; Sessa F; Capella C
    Virchows Arch; 2017 Jul; 471(1):13-21. PubMed ID: 28550498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.
    Maisonneuve P; Disalvatore D; Rotmensz N; Curigliano G; Colleoni M; Dellapasqua S; Pruneri G; Mastropasqua MG; Luini A; Bassi F; Pagani G; Viale G; Goldhirsch A
    Breast Cancer Res; 2014 Jun; 16(3):R65. PubMed ID: 24951027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.